Peroxisome proliferator-activated receptor-b/d (PPARb/d) inhibits skin tumorigenesis through mechanisms that may be dependent on HRAS signaling. The present study examined the hypothesis that PPARb/d promotes HRAS-induced senescence resulting in suppression of tumorigenesis. PPARb/d expression increased p-ERK and decreased p-AKT activity. Increased p-ERK activity results from the dampened HRAS-induced negative feedback response mediated in part through transcriptional upregulation of RAS guanyl-releasing protein 1 (RASGRP1) by PPARb/d. Decreased p-AKT activity results from repression of integrin-linked kinase (ILK) and phosphoinositide-dependent protein kinase-1 (PDPK1) expression. Decreased p-AKT activity in turn promotes cellular senescence through upregulation of p53 and p27 expression. Both over-expression of RASGRP1 and shRNA-mediated knockdown of ILK partially restore cellular senescence in Pparb/d-null cells. Higher PPARb/d expression is also correlated with increased senescence observed in human benign neurofibromas and colon adenoma lesions in vivo. These results demonstrate that PPARb/d promotes senescence to inhibit tumorigenesis and provide new mechanistic insights into HRAS-induced cellular senescence.
INTRODUCTION
PPARb/d is a nuclear receptor that has many normal biological functions. Acting primarily as a transcription factor, PPARb/d promotes terminal differentiation, 1, 2 inhibits inflammatory signaling 3 and increases skeletal muscle fatty acid catabolism. 4 The role of PPARb/d in some cancers remains controversial, but there is strong experimental evidence that PPARb/d attenuates non-melanoma skin cancer. 2 Pparb/d-null mice exhibit exacerbated skin tumorigenesis, and ligand activation of PPARb/ d inhibits chemically induced skin tumorigenesis; this is likely mediated by PPARb/d-dependent induction of terminal differentiation and inhibition of cell proliferation and mitosis. [5] [6] [7] [8] [9] Mutations in the Harvey sarcoma ras virus gene (Hras) is found in 490% of 7,12-dimethylbenz[a]anthracene (DMBA)-initiated skin tumors 10 and increased activity associated with mutant HRAS is one mechanism that can cause cancer. 11 An activated mutant HRAS (Hras-V12) triggers cellular senescence (irreversible cell cycle arrest), concomitant with increased expression of p16 and p53 tumor suppressors. 12 Oncogene-induced senescence has also been observed for a number of mutations in other genes including KRAS, BRAF, PTEN and NF1. 13 Thus, it is widely believed that oncogene-induced senescence serves as a selfdefense mechanism to suppress tumor development by preventing the progression of benign lesions to malignancies in the absence of additional cooperating mutations. 13 The present study examined the mechanisms by which PPARb/d attenuates HRAS-dependent skin tumorigenesis, with an emphasis on cellular senescence.
RESULTS

PPARb/d promotes HRAS-induced senescence and suppresses malignant conversion
A complete carcinogen bioassay using DMBA was performed because mutant Hras skin tumors produced through this method have differential sensitivity to malignant conversion.
14 A higher percentage of malignant squamous cell carcinomas and a lower percentage of benign papillomas in Pparb/d-null mice compared with wild-type controls were observed ( Figure 1a ). The distribution of tumor type was not influenced by ligand activation of PPARb/d with GW0742 ( Figure 1a ). This suggests that PPARb/d may suppress malignant conversion of skin tumors. The lack of effect by an exogenous ligand could be due to the presence of highaffinity endogenous ligand(s). To further characterize the role of PPARb/d in malignant transformation of skin tumors with an Hras mutation, an in vitro malignant conversion assay was performed. This assay uses primary keratinocytes infected with an oncogenic HRAS retrovirus 15 that confers a malignant phenotype characterized by resistance to calcium-induced differentiation and cell cycle arrest. 16 Expression of proteins downstream of HRAS activation in HRAS-expressing keratinocytes, including p-ERK and p-AKT, is comparable to that of two skin cancer cell lines with mutant Hras (Supplementary Figure S1a) . HRAS-expressing Pparb/ d-null cells developed calcium-resistant foci (Figure 1b ) that are bromodeoxyuridine (BrdU)-positive, whereas HRAS-expressing wild-type cells do not (Figure 1c ). Ligand activation of PPARb/d had no influence on foci in either genotype ( Figure 1b) . As oncogenic HRAS could trigger cellular senescence to prevent malignant transformation in primary cells, 12, 17 and wild-type HRAS-expressing keratinocytes cultured in high calcium medium exhibited morphology reminiscent of cellular senescence (data not shown), the expression of senescence-associated b-galactosidase (b-gal) and BrdU labeling indices were examined. A higher percentage of BrdU labeling and lower percentage of b-gal-positive cells was noted in HRAS-expressing Pparb/d-null compared with wild-type cells (Figures 1d and e) . Surprisingly, ligand activation of PPARb/d decreased both the percentage of b-gal-and BrdU-positive cells in HRAS-expressing wild-type but not in Pparb/d-null cells (Figures 1d and e) . Around 75% of papillomas from wild-type mice and 33% of papillomas from Pparb/d-null mice stained positive for b-gal, and no squamous cell carcinoma from either genotype were positive for b-gal (Figure 1f ). This is consistent with previous studies showing that benign skin papillomas undergo senescence, whereas malignant tumors do not. 18, 19 PPARb/d promotes senescence by regulating PI3K/AKT and MEK/ ERK signaling Expression of proteins downstream of HRAS signaling was examined to determine whether PPARb/d differentially regulated these pathways. Four to five days after introduction of oncogenic HRAS, there was higher phosphorylated MEK (p-MEK), p-ERK ( Figure 2a ) and HRAS-GTP (Figure 2b ) in wild-type compared with Pparb/d-null keratinocytes. In contrast, a higher level of phosphorylated AKT (p-AKT) was observed in HRAS-expressing Pparb/ d-null cells as compared with wild-type (Figure 2c ). At a later time point (day 11), higher expression of proteins inducing senescence 12, 20, 21 (p53, p21 and p27) was observed in wild-type cells compared with Pparb/d-null cells (Figure 2d ). While ligand activation of PPARb/d with GW0742 caused a decrease in p-MEK, p-ERK and GTP-bound HRAS in HRAS-expressing wild-type cells (Figures 2a and b) , this is likely due to the fact that ligandactivated PPARb/d selects against cells with higher HRAS expression. 9 This might explain why ligand activation of PPARb/ d had no effect on p53, p21 and p27 in HRAS-expressing wild-type cells.
The higher levels of p-MEK and p-ERK and lower level of p-AKT in wild-type cells (Figures 2a-c ) correlated with higher markers of senescence ( Figure 2d ) and this was not found in HRAS-expressing Pparb/d-null cells (Figures 2a-d) . Thus, the hypothesis that PPARb/ d promotes senescence during the early stages of HRAS activation by inhibiting PI3K/AKT and maintaining MEK/ERK signaling pathways was examined. Inhibition of MEK1 with PD98059 delayed HRAS-induced senescence in both wild-type and Pparb/d-null cells (Figure 2e, Supplementary Figure S1b) . Over-expression of a constitutively active MEK 22 increased HRAS-induced senescence in both wild-type and Pparb/d-null cells, but the effect was more pronounced in Pparb/d-null cells (Supplementary Figure S1c, e, f) . In contrast, inhibition of PI3K with LY294002 had no effect on HRAS-induced senescence in wild-type cells, but significantly increased HRAS-induced senescence in Pparb/d-null cells (Figure 2e ). The same effects were also observed with overexpression of PTEN (Supplementary Figure S1d-f) . Interestingly, Pparb/d-null cells are also more sensitive to inhibition of cell proliferation by treatment with LY294002 and less sensitive to inhibition of cell proliferation by treatment with PD98059 (Supplementary Figure S1g) . Further, inhibition of PI3K/AKT by LY294002 caused a modest increased in expression of p53 and p21 and marked increase of p27 in HRAS-expressing Pparb/d-null keratinocytes to a level similar to that of HRAS-expressing wildtype keratinocytes (Figure 2f ). Combined, these data suggest that PPARb/d promotes senescence by regulating PI3K/AKT and the MEK/ERK pathway.
The mechanism by which PPARb/d maintains expression of p53, p21 and p27 in HRAS-expressing keratinocytes was investigated.
Phosphorylation of MDM2 at S166/S186 by p-AKT can activate its ubiquitin ligase activity toward p53, 23 causing reduced expression of p53. Relatively lower expression of p-MDM2 and higher p53 was found in HRAS-expressing wild-type cells compared with Pparb/dnull cells (Figure 2f ). Inhibition of p-AKT with LY294002 caused a decrease in p-MDM2 and an increase in p53 in Pparb/d-null cells (Figure 2f ). p27 and p21 are both positively regulated by FOXO, a transcription factor that is inhibited by p-AKT. 24 Lower FOXO activity was found in HRAS-expressing Pparb/d-null cells compared with controls (Figure 2g ). In addition, gene set enrichment analysis from a microarray data set 9 shows lower FOXO target gene expression in HRAS-expressing Pparb/d-null cells compared with control (Supplementary Figure S2a, b) . To determine whether the higher FOXO activity observed in HRAS-expressing wild-type cells and the higher MDM2 activity observed in Pparb/d-null cells underlie the different senescent phenotypes, FOXO and MDM2 activity was blocked using specific inhibitors to FOXO1 25 Figure S2c ) and the expression of p53 (Figure 2j ). These data collectively suggest that PPARb/d represses AKT activity, leading to enhanced FOXO activity and decreased MDM2 activity, causing increased expression of proteins that facilitate senescence such as p27, p21 and p53.
PPARb/d upregulates RASGRP1 to promote HRAS-induced senescence Microarray analysis from a previously published study 9 identified PPARb/d target genes involved in HRAS-induced senescence. Expression of the negative RAS regulator RASGAP120 was increased and the positive RAS regulator RASGRP1 was decreased in response to HRAS activation, respectively ( Figures  3a and b) . Interestingly, expression of RASGAP120 was significantly higher, whereas expression of RASGRP1 was lower in HRASexpressing Pparb/d-null cells compared with wild-type cells (Figures 3a and b) . In response to HRAS activation, expression of mRNA encoding the negative RAS regulator Rasa4 was increased in cells from both genotypes, but relatively higher expression of Rasa4 mRNA was also observed in HRAS-expressing Pparb/d-null cells compared with wild-type cells (data not shown). No change in expression of the MAP kinase phosphatase DUSP1, a negative RAS regulator, was found in wild-type cells in response to HRAS activation, however, increased expression of DUSP1 was found in Pparb/d-null cells in response to HRAS activation (Figures 3a and  b) . A similar effect was observed for the mRNA encoding the negative RAS regulator Dusp3 (data not shown). These data are consistent with a previous study showing a negative feedback response to HRAS activation, whereby expression of negative RAS regulators is increased and expression of positive regulators is decreased in an attempt to impede RAS signaling. 27 Combined, these results suggest that PPARb/d attenuates this HRAS-induced negative feedback response.
The time course of HRAS-GTP formation was examined to determine whether the PPARb/d-dependent regulation of the negative and positive RAS regulators modulates HRAS activity. Consistent with relatively higher expression of RASGRP1 in HRASexpressing wild-type keratinocytes (Figures 3a and b) , accumulation of HRAS-GTP was greater in HRAS-expressing wild-type keratinocytes compared with Pparb/d-null cells (Figure 3c ). This is consistent with a study showing that deficiency in RASGRP1 resulted in decreased level of RAS-GTP in mouse keratinocytes. 28 The PPARb/d-dependent difference in HRAS-GTP accumulation is 
mice topically treated with or without GW0742 was quantified. SCC, squamous cell carcinoma; SCP, squamous cell papilloma; KA, keratoacanthoma; BBCT, benign basal cell tumor. Using a two-proportion z-test, significant differences (Pp0.05) were found in the percentage of squamous cell papillomas between wild-type and Pparb/d-null controls, the percentage of squamous cell papillomas between GW0742-treated wild-type and Pparb/d-null, and the percentage of squamous cell carcinomas between GW0742-treated wild-type and Pparb/d-null. No significant differences in the percentage of squamous cell papillomas or squamous cell carcinomas were found between control and GW0742 groups in either genotype. The percentage of squamous cell carcinomas between wild-type and Pparb/d-null controls was not statistically significant. However, a higher percentage of keratoacanthomas was found in control Pparb/d-null mice compared with wild-type. Keratoacanthomas can convert to squamous cell carcinoma in mice with prolonged promotion, 72 signaling typically observed in Pparb/d-null mice. 5 Thus, it is important to note that there are significantly more combined squamous cell carcinomas and keratoacanthomas in control and/or GW0742-treated Pparb/d-null mice compared with similarly treated wild-type mice. These data suggest that loss of PPARb/d promotes the conversion of keratoacanthomas to squamous cell carcinomas. unlikely related to differences in expression of RASGAP120 because HRAS with mutations at codons 12 and 61 is resistant to the GTP hydrolase activity associated with RASGAP120. 
To determine whether higher RASGRP1 expression promotes cellular senescence, RASGRP1 was over-expressed in HRASexpressing cells. Ectopic expression of RASGRP1 increased p-ERK ( Figure 3f ) and restored cellular senescence in Pparb/d-null cells (Figure 3g) , concomitant with increased expression of the senescence markers DcR2 and p53 (Figure 3h ). These data suggest that PPARb/d positively regulates RASGRP1 to promote HRAS-induced senescence.
PPARb/d represses ILK to promote HRAS-induced senescence ILK and PDPK1 are known to phosphorylate AKT at Ser473 and Thr308, respectively, to fully activate AKT. 30, 31 Consistent with past studies, [32] [33] [34] expression of ILK and PDPK1 was higher in control and HRAS-expressing Pparb/d-null cells (Figure 4a,   Supplementary Figure S4a) . In silico examination of the Ilk gene revealed two potential PPREs in the second intron (Figure 4b) . No occupancy of PPARb/d on the downstream PPRE was found (data not shown). Higher PPARb/d occupancy on the upstream PPRE was associated with increased occupancy of histone deacetylase 1 (HDAC1) and HDAC3 and decreased AcH4 in both mock and HRAS-expressing wild-type cells compared with Pparb/d-null counterparts but ligand activation of PPARb/d had no effect on these endpoints (Figure 4c) . Interestingly, mutating the PPARb/d binding half-site in a luciferase reporter construct containing the upstream PPRE (Figure 4b ) abolished the repression of ILK by PPARb/d (Supplementary Figure S4b) . Overexpression of PPARb/d in HaCaT cells also caused repression of ILK, PDPK1 and p-AKT, and these changes in expression were associated with decreased AcH4 and increased promoter To determine whether higher ILK expression repressed cellular senescence, ILK expression was knocked down by shRNA in Pparb/ d-null cells. Of the two shRNAs used, only shRNA1 successfully knocked down ILK by 50% (Figure 4e ). Decreased ILK expression caused a decrease in p-AKT and restored cellular senescence, concomitant with increased expression of the senescence markers p53, p27 and decreased expression of the cell proliferation marker phospho-retinoblastoma (pRB; S780) in Pparb/d-null cells (Figures  4d and e) . These effects were not due to an increase in p-ERK following ILK knockdown (Figure 4e) . Furthermore, knockdown of ILK partially restored cellular senescence in three out of six calcium-resistant HRAS-expressing Pparb/d-null clones isolated from an assay as shown in Figure 1b (Figure 4f) . Results from experiments where RASGRP1 is over-expressed (Figures 3f-h) or ILK is knocked down (Figures 4d-f ) collectively suggest that both decreased p-ERK activity and increased p-AKT activity is required to evade HRAS-induced senescence.
PPARb/d promotes HRAS-induced senescence in fibroblasts
To confirm that the observed decreased HRAS-induced senescence in Pparb/d-null keratinocytes is also observed in other cell types, mouse and human fibroblasts expressing oncogenic HRAS were examined. Decreased HRAS-induced senescence was observed in Pparb/d-null dermal fibroblasts as compared with wild-type cells (Figures 5a and b) . Decreased mRNA expression of the senescence markers p16 and p21 was observed in HRASexpressing Pparb/d-null dermal fibroblasts as compared with controls ( Figure 5c ). In addition, Rasgrp1 mRNA was lower and Ilk and Rasgap120 mRNA were higher in HRAS-expressing Pparb/dnull dermal fibroblasts (Figure 5c ), all of which recapitulate the changes found in primary keratinocytes. The human BJ fibroblast cell line was also examined to confirm the PPARb/d-dependent effects observed in mouse cells. Decreased HRAS-induced senescence was observed following knockdown of PPARb/d by shRNA in BJ cells expressing mutant HRAS (Figures 5d and e) . Further, in BJ cells expressing mutant HRAS following knockdown of PPARb/d, RASGRP1 mRNA was decreased, ILK mRNA was increased and HRAS-induced expression of p16, p21 and DcR2 was reduced (Figures 5f and g ). Additionally, HRAS-induced expression of p-ERK and p-AKT was repressed and enhanced, respectively, following knockdown of PPARb/d in BJ cells expressing mutant HRAS (Figures 5f and g ).
PPARb/d attenuates ILK/p-AKT to promote senescence in mouse skin tumors To test the hypothesis that PPARb/d promotes HRAS-induced senescence in vivo, chemically induced skin tumors were examined. b-gal-positive regions of papillomas also stained positive for p27 but were negative for p-AKT (S473) in both wild-type and Pparb/d-null mice (Figure 6a ). Squamous cell carcinoma were negative for b-gal but exhibited strong expression of p-AKT (S473) and essentially no p27 expression (Figure 6a ). Increased p-AKT staining was found in tumors from Pparb/d-null mice compared with wild-type counterparts (Figures 6b and c) . These findings are consistent with analysis of HRAS-expressing keratinocytes showing that p-AKT inhibits FOXO and p27 expression (Figures 2f and g ). More Ki-67 positive cells were found in tumors from Pparb/d-null mice as compared with tumors examined from wild-type mice (Figure 6b ). This suggests that PPARb/d inhibits the proliferative capacity of skin tumors. Higher expression of ILK, p-AKT (S473, T308) was also found in skin tumors from Pparb/d-null mice compared with wild-type mice ( Figure 6d ). Further, a negative correlation between p-AKT and the senescence marker p16 was also found (Figure 6d ). These findings suggest that the anti-tumorigenic role of PPARb/d in promoting senescence is mediated by repressing ILK/p-AKT signaling.
PPARb/d promotes cellular senescence in human benign lesions To determine whether the changes observed in mouse models were also found in human tumors, the correlation between PPARb/d expression and the senescence marker p16 in human benign dermal neurofibroma lesions was examined. These lesions were chosen because: (1) benign dermal neurofibromas harbor an NF1 loss-of-function mutation, resulting in activation of RAS signaling pathway 27 similar to the activated HRAS model used in the present studies and (2) b-gal-positive staining of senescent cells are found in these lesions. 27 Examination of a publicly available database 35 revealed that expression of mRNA encoding the senescence marker p16 is significantly higher in benign dermal neurofibromas and NF1-derived primary benign neurofibroma Schwann cells compared with malignant peripheral nerve sheath tumors and cell lines, respectively (Figure 7a ). This suggests that p16 mRNA is a good senescence marker in these types of lesions. Neurofibromas are heterogeneous tumors that consist of Schwann cells with initiating homozygous NF1 mutations, but also recruited fibroblasts, peripheral cells, neurons and mast cells that are only heterozygous for NF1 mutations. As bgal-positive staining was only found in cells with homozygous loss-of-function NF1 mutations, 27 eight samples of NF1-derived primary benign neurofibroma Schwann cells with a homozygous NF1 mutation were examined. A positive correlation between PPARb/d and p16 mRNA was found in these cells (Figure 7b ). In addition, a positive correlation was also found between PPARb/d and RASGPR1 (Figure 7b ), similar to the effects observed in the mouse models. While no correlation between PPARb/d and ILK mRNA was found, a negative correlation between PPARb/d and PDPK1 mRNA was found in these cells (Figure 7b ). Human colon adenomas were also examined because (1) they contain cells exhibiting both strong p16 immunoreactivity and the absence of Ki-67 staining, as previously reported, 36, 37 and (2) the KRAS oncogene is mutated in B35-45% of colorectal cancers. 38 In the five human colon adenomas that contained a KRAS mutation at codon 13 (data not shown), the average PPARb/d protein level was higher compared with untransformed colon (Figure 7c ). In addition, PPARb/d protein in both normal colon and colon adenomas negatively correlated with both mRNA and protein of ILK and p-AKT (Figure 7c ). The expression of PPARb/d protein in colon adenomas also positively correlates with expression of senescence markers (Figure 7c ). These data suggest that PPARb/d promotes cellular senescence in benign human tumors.
DISCUSSION
Results from these studies are the first to show that PPARb/d promotes HRAS-induced senescence in keratinocytes and skin tumors. PPARb/d promotes senescence by enhancing the RAF/ MEK/ERK pathway and inhibiting the PI3K/AKT pathway during HRAS-induced neoplastic transformation. These studies also demonstrated that increased p-ERK and decreased p-AKT activities are both required to facilitate senescence. This conclusion is supported by several studies that showed that higher p-ERK activity could trigger senescence by upregulating expression of p16 and p21. 20, 39, 40 This is consistent with data from the present studies showing that higher PPARb/d expression in benign tumors is associated with higher expression of p16. Further, results from the present studies are consistent with other studies showing that high PI3K/AKT activity can prevent HRASinduced senescence by inhibiting FOXO activity and increasing MDM2 activity that collectively cause reduced expression of p27, p21 and p53. 27, 41 Among these senescence markers, the most robust change observed in Pparb/d-null keratinocytes was the marked reduction of p27. p27 has been previously shown to promote senescence in multiple tissues and loss of p27 expression led to downregulation of senescence and progression of cancer. 21, [42] [43] [44] Collectively, these results suggest that PPARb/d inhibits AKT activity causing (1) increased FOXO activity, thereby preventing downregulation of p27 and p21 caused by activation of HRAS and (2) decreased p-MDM2 activity, thereby preventing downregulation of p53 mediated by activation of HRAS (Figure 8 ). Higher PI3K/AKT signaling can also counteract senescence by stimulating cell survival by phosphorylation of many substrates. 45 The fact that inhibition of AKT didn't promote senescence in wild-type HRAS-expressing keratinocytes, whereas inhibition of AKT in Pparb/d-null keratinocytes did promote senescence suggests that different threshold levels of p-AKT may be required for promoting pro-survival versus an anti-senescence function of p-AKT.
It was recently shown that mutations in NF1, RAF and RAS can induce a negative feedback response, whereby expression of negative RAS regulators is increased and expression of positive regulators is decreased to suppress RAS signaling, thereby promoting senescence by subsequent inhibition of PI3K/AKT activities. 27 This negative feedback response was also observed in the present studies. Interestingly, PPARb/d dampens this negative response without increasing the level of p-AKT. This suggests that PPARb/d promotes HRAS-induced cellular senescence by (1) attenuating the negative feedback response causing higher levels of p-ERK and (2) preventing an increase of p-AKT level by repressing ILK and PDPK1 expression (Figure 8 ). [55] [56] [57] [58] [59] [60] [61] [62] and a recent study showed that colorectal cancer patients with relatively low expression of PPARb/d in the primary tumor were nearly four times as likely to die from this disease as compared with patients with relatively higher expression of PPARb/d in their primary tumors. 63 This suggests that PPARb/d may inhibit colon tumorigenesis by promoting cellular senescence resulting in benign lesions and that downregulation of PPARb/d is required to evade senescence and lead to malignant conversion. As colon tumors can have different mutations (KRAS, P53, APC, and so on), it will be of interest to examine whether PPARb/d exerts prosenescence effects only in the presence of specific mutations like KRAS or promotes senescence independently of mutation type(s).
MATERIALS AND METHODS Plasmids
pBABE-puro-Pten was obtained by cloning mouse Pten into pBABE-puro and pBABE-puro-Mek-DD, 64 and pWZL-hygro-H-RASV12 were purchased (Addgene, Cambridge, MA, USA). pBABE-puro-Rasgrp1 was obtained by cloning the mouse Rasgrp1 open reading frame from a shuttle clone vector (GC-Mm04880; GeneCopoeia, Rockville, MD, USA). The plasmid containing a mouse shRNA against Ilk, two human shRNAs against PPARb/d or a nontarget control shRNA were purchased from Mission shRNA (Sigma-Aldrich, St Louis, MO, USA). The shRNA catalog numbers are mouse Ilk shRNA1 (TRCN0000022515), mouse Ilk shRNA2 (TRCN0000022518), human PPARb/d shRNA (TRCN0000001661), human PPARb/d shRNA (TRCN0000010647) and non-target control shRNA (SHC002).
Cell culture
Primary keratinocytes from newborn wild-type and Pparb/d-null mice were prepared and cultured as previously described. 65 The HaCat cell line was cultured in DMEM medium as previously described. 66 To activate PPARb/d, GW0742 (1 mM) was used as this is within the range that specifically activates PPARb/d in keratinocytes.
9,67 LY294002 (10 mM) was used to inhibit PI3K activity and PD98059 (10 mM) was used to inhibit MEK activity because these concentrations are within the range that specifically inhibits these enzymes. 27 Complete carcinogenesis bioassay Wild-type or Pparb/d-null, female mice (6-8 weeks of age) were initiated with 50 mg of DMBA dissolved in 200 ml acetone (5-7 mice per group). Mice were treated topically with 50 mg of DMBA weekly for 30 weeks. Mice were also topically treated with acetone or 5 mM GW0742 twice a week during this 30-week treatment period. After 30 weeks, mice were killed and tumor samples were either fixed or snap-frozen in liquid nitrogen for further analysis. Fixed tumor samples were embedded in paraffin, sectioned and stained with hematoxylin and eosin and scored for benign or malignant pathology by examination with a light microscope. Senescence-associated b-galactosidase (b-gal) assay Cytochemical detection of senescence-associated b-gal activity was determined in cells and tumors as described. 68 Flow cytometry analysis Cells were stained with BrdU and propidium iodide (PI) and analyzed for cell cycle progression as previously described. 69 RNA isolation and quantitative real-time PCR (qPCR) Total RNA was isolated using TRIZOL reagent (Invitrogen, Carlsbad, CA, USA) and reverse transcription and qPCR was performed as previously described. 70 The relative level of mRNA was normalized to glyceraldehyde 3-phosphate dehydrogenase (Gapdh) or 18s mRNA.
Quantitative western blot analysis
